Board of Directors
Click on board member name to see their bio.
Mr. Clifford J. StocksChief Executive Officer
- Mr. Stocks joined Theraclone Sciences in December 2011 as Chief Executive Officer. Most recently Mr. Stocks served as Chief Business Officer of Calistoga Pharmaceuticals, Inc., where he led the partnering activities and M&A teamwork that resulted in the acquisition of Calistoga by Gilead for $600 million in Q2 2011. Mr. Stocks brings more than two decades of experience in the biotech industry, including 15 years at ICOS Corporation where he served as an Executive Officer and Vice President of Business Development. While at ICOS, he led acquisitions and joint venture activities, as well as alliance formation, strategy, licensing and deal making. He played an instrumental role on the leadership team that developed and launched Cialis®, and was a key architect of the Lilly ICOS joint venture partnership leading to the $2.3 billion acquisition of ICOS in 2007. Mr. Stocks's early career includes a turn as a management consultant in the Health Services practice of Booz, Allen & Hamilton, as well as academic research in the department of immunology at the University of Utah and the department of molecular genetics and cell biology at the University of Chicago. He received a Master of Business Administration degree from the University of Chicago, Booth Graduate School of Business and a Bachelor of Science degree in biology from the University of Utah.
Steven Gillis, Ph.D.Chairman, Theraclone Sciences; Managing Director, ARCH Venture Partners
- Steven Gillis, Ph.D. is a Managing Director at ARCH Venture Partners, focused on the evaluation of new life science technologies and also on the development and growth of ARCH’s biotechnology portfolio companies. Dr. Gillis was a founder and director of Corixa Corp. and served as the company’s Chief Executive Officer since inception and as its Chairman since January of 1999. Corixa was acquired by GlaxoSmithKline in July of 2005. Prior to starting Corixa, Dr. Gillis was a founder and director of Immunex Corp. From 1981 until his departure in 1994, Dr. Gillis served as Immunex’s Director of Research and Development, Chief Scientific Officer, and Chief Executive Officer of Immunex’s Research and Development subsidiary. Dr. Gillis was interim Chief Executive Officer of Immunex Corp. following its majority purchase by American Cyanamid Co. and he remained a member of the Board of Directors until 1997. Immunex was acquired by Amgen Inc. in 2002. Dr. Gillis is an immunologist by training and is credited as being a pioneer in the field of cytokines and cytokine receptors, directing the development of multiple marketed products, including Leukine®, Prokine®, Enbrel®, and Bexxar®. Dr. Gillis received his B.A. from Williams College in 1975 and his Ph.D. from Dartmouth College in 1978.
Wende HuttonGeneral Partner, Canaan Partners
Seasoned healthcare investor Wende Hutton is passionate about identifying, investing in and building companies that are revolutionizing the practice of medicine. She joined Canaan in 2004, bringing diverse expertise from across the entire medical spectrum. Over the last 15 years, Wende has facilitated the market entrance of over 11 novel and lifesaving medical devices, new drugs and diagnostics. Her track record is a testament to her leadership and includes the initial public offerings of five companies, of which two were later acquired, and the acquisition of three more by medical companies. Wende began her venture career at Mayfield Fund in 1993, where she was a General Partner in the life sciences group until 2001. During her tenure at Mayfield, Wende incubated Heartstream Inc. (HPQ) and Northstar Neuroscience Inc. (NSTR), working closely with those founding teams. Most recently, she was a General Partner at Spring Ridge Ventures, a healthcare-focused seed fund. Earlier in her career, Wende held senior operational management positions at GenPharm International and Nellcor in business development and marketing.
Wende sits on the boards of Alsius Corp (Nasdaq: ALUS), Apieron Inc., BiPar Sciences, Inc., Calibra Medical, ReVision Optics, Inc. and Theraclone Sciences. Her previous board seats include Heartstream, Inc. (acquired by Hewlett Packard), Micro Therapeutics, Inc. (acquired by ev3, Inc.), Northstar Neuroscience (NSTR), Orquest, Inc. (acquired by Johnson & Johnson), and SenoRx, Inc. (NASDAQ: SENO).
Wende holds an AB in human biology from Stanford University and an MBA from Harvard Business School, where she was a Baker Scholar. She is an active member of several community service groups, including serving as task-force leader on obesity for the Santa Clara and Mid-Peninsula YMCAs. Beyond her community service involvements, Wende’s first love is a field biology hike or lecture.
Christopher K. Mirabelli, Ph.D.Managing Director, HealthCare Ventures, LLC (HCV)
Dr. Mirabelli has been a Managing Director at HealthCare Ventures, LLC (HCV) since 2000. HCV, founded in 1985, is a leading venture capital group focused on investing in and building significant companies in the biopharmaceutical industry. HCV has raised over $1.6 billion in eight funds. Dr. Mirabelli serves as Chairman of the Board of Directors of Sequoia Pharmaceuticals, Inc., and as a member of the Board of Directors of CellGate, Inc., Critical Therapeutics, Inc., DecImmune Therapeutics, Inc., Galleon Pharmaceuticals, Inc. and Synovex Corporation.
Prior to joining HealthCare Ventures, Dr. Mirabelli served as Chairman of the Board and Chief Executive Officer of LeukoSite, Inc. from 1993 through 1999. LeukoSite merged with Millennium Pharmaceuticals in December 1999. Dr. Mirabelli presided over the integration of LeukoSite into Millennium as President of Pharmaceutical R&D and a member of the Company’s Board of Directors until mid-2000. Dr. Mirabelli was a founder of Isis Pharmaceuticals, Inc., where he served in a number of senior research and development positions from 1989 to 1993. He was a member of SmithKline and French Laboratories R&D Division from 1981 to 1988 where he held a number of positions including Director of the Department of Molecular Pharmacology. Dr. Mirabelli received his Ph.D. degree in molecular pharmacology from Baylor College of Medicine in Houston, Texas in 1981.
Dr. Wendye RobbinsAssociate Professor, Stanford University School of Medicine
Dr. Robbins’ medical specialty is pain. She maintains an active appointment as Associate Professor at the Stanford University School of Medicine, Division of Pain Management. She mentors housestaff, coordinates patient care, and supervises fellows in their study of neuropharmacology.
Dr. Robbins has extensive experience directing small and large molecule development from discovery through translational research through clinical development. Dr. Robbins founded two biopharmaceutical companies, Limerick BioPharma and NeurogesX, Inc. (NASD: NGSX), invented the intellectual property for both, and oversaw a range of clinical trials. She held positions of Chief Executive Officer, President, and Chief Medical Officer, and raised over $100M US for both companies. Dr. Robbins has also been a scientific and strategic advisor to many nascent biotech and pharmaceutical companies.
Dr. Robbins received her BS from the University of California, Berkeley and her MD from the Medical College of Pennsylvania. She completed postgraduate training in internal medicine at the Hospital of the University of Pennsylvania and in anesthesiology and pain at the Johns Hopkins University Medical Institutions. She is board certified in anesthesiology.